Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Austrian Agency for Health and Food Safety (AGES), Vienna, Austria.
Eur J Clin Invest. 2021 Apr;51(4):e13520. doi: 10.1111/eci.13520. Epub 2021 Feb 21.
A key question concerning coronavirus disease 2019 (COVID-19) is how effective and long lasting immunity against this disease is in individuals who were previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We aimed to evaluate the risk of SARS-CoV-2 re-infections in the general population in Austria.
This is a retrospective observational study using national SARS-CoV-2 infection data from the Austrian epidemiological reporting system. As the primary outcome, we aim to compare the odds of SARS-CoV-2 re-infections of COVID-19 survivors of the first wave (February to April 30, 2020) versus the odds of first infections in the remainder general population by tracking polymerase chain reaction (PCR)-confirmed infections of both groups during the second wave from September 1 to November 30, 2020. Re-infection counts are tentative, since it cannot be excluded that the positive PCR in the first and/or second wave might have been a false positive.
We recorded 40 tentative re-infections in 14 840 COVID-19 survivors of the first wave (0.27%) and 253 581 infections in 8 885 640 individuals of the remaining general population (2.85%) translating into an odds ratio (95% confidence interval) of 0.09 (0.07 to 0.13).
We observed a relatively low re-infection rate of SARS-CoV-2 in Austria. Protection against SARS-CoV-2 after natural infection is comparable with the highest available estimates on vaccine efficacies. Further well-designed research on this issue is urgently needed for improving evidence-based decisions on public health measures and vaccination strategies.
关于 2019 年冠状病毒病(COVID-19)的一个关键问题是,以前感染过严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的个体对这种疾病的免疫力有多有效和持久。我们旨在评估奥地利普通人群中 SARS-CoV-2 再次感染的风险。
这是一项使用奥地利流行病学报告系统的国家 SARS-CoV-2 感染数据的回顾性观察性研究。作为主要结果,我们旨在通过跟踪两组在 2020 年 9 月 1 日至 11 月 30 日的第二波中聚合酶链反应(PCR)确认的感染,比较第一波(2020 年 2 月至 4 月 30 日)COVID-19 幸存者与其余普通人群中首次感染的 SARS-CoV-2 再感染的几率。再感染计数是暂定的,因为不能排除第一波和/或第二波中的阳性 PCR 可能是假阳性。
我们记录了第一波 COVID-19 幸存者中的 40 例暂定再感染(0.27%)和剩余普通人群中的 253 581 例感染(2.85%),这转化为比值比(95%置信区间)为 0.09(0.07 至 0.13)。
我们观察到 SARS-CoV-2 在奥地利的再感染率相对较低。自然感染后对 SARS-CoV-2 的保护作用与疫苗效力的最高现有估计值相当。需要进一步对此问题进行精心设计的研究,以改善基于证据的公共卫生措施和疫苗接种策略决策。